Chemours director Alister Cowan buys $203,060 of company stock

The Chemours Company (NASDAQ:CC) witnessed a notable insider transaction on August 7, 2026, as director Alister Cowan acquired 13,000 shares of the company's common stock for a total of $203,060. The shares were bought at a weighted average price of $15.62 per share, within a range of $15.58 to $15.62 per share. After executing this transaction, Mr. Cowan’s beneficial ownership in Chemours amounted to 56,988.0387 shares, encompassing directly held shares, restricted stock units, and dividend equivalent units.

Concurrently, Chemours' stock was trading at $15.85, reflecting a 36% increase year-to-date, but a 22% decline over the preceding six months. Analysts, through InvestingPro insights, anticipate the company to achieve profitability this year despite recent earnings revisions.

Meanwhile, Chemours reported mixed second-quarter 2026 results, with adjusted earnings and sales falling short of Wall Street expectations. The company disclosed earnings of $0.42 per share on revenue of $1.59 billion, underperforming the estimated $0.50 per share and $1.66 billion in sales. This financial setback coincided with UBS downgrading Chemours from a Buy rating to Neutral.

The downgrade was attributed to concerns over the earnings potential of Chemours' refrigerant business, TSS, attributed to destocking and anticipated market share loss in 2026. UBS also revised its price target from $29.00 to $18.00.

These developments have garnered significant attention from investors closely tracking Chemours' performance and market position.